PRODH Regulates Tamoxifen Resistance through Ferroptosis in Breast Cancer Cells
Genes · 2024
DOI: 10.3390/genes15101316 ↗Kurz gefasst
Fachartikel in der Zeitschrift Genes, 2024. Verfasst von Ping Zhang und 8 weiteren Autor:innen. Beteiligte Einrichtung: The Department of Biochemistry, Medicine School, Yichun University, Yichun 336000, China. Hauptthemen laut MEDLINE: Tamoxifen, Ferroptosis, Breast Neoplasms, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Education Department of Jiangxi Province, Science and Technology project of Education Department of Jiangxi Province.
Abstract (Originalsprache)
Background
Estrogen receptor-positive breast cancer accounts for around 70% of all cases. Tamoxifen, an anti-estrogenic inhibitor, is the primary drug used for this type of breast cancer treatment. However, tamoxifen resistance is a major challenge in clinics. Metabolic reprogramming, an emerging hallmark of cancer, plays a key role in cancer initiation, progression, and therapy resistance. The metabolism of non-essential amino acids such as serine, proline, and glutamine is involved in tumor metabolism reprogramming. Although the association of glutamine metabolism with tamoxifen resistance has been well established, the role of proline metabolism and its critical enzyme PRODH is unknown.
Objective
The aim of this study is to explore the role and mechanism of PRODH in tamoxifen resistance in breast cancer cells.
Methods
PRODH and GPX4 expressions in tamoxifen-resistant cells were detected using real-time PCR and Western blot analysis. The breast cells’ response to tamoxifen was measured using MTT assays. Trans-well assays were used to detect cell migration and invasion. A Xenograft tumor assay was used to detect the role of PRODH in tumor growth. Reactive oxygen species were measured using flow cytometry.
Results
PRODH expression is reduced in tamoxifen-resistant cells, and its overexpression enhances tamoxifen response in vitro and in vivo. Conversely, PRODH knockdown confers tamoxifen resistance in tamoxifen-sensitive cells. Mechanistic studies show that ferroptosis is inhibited in tamoxifen-resistant cells and overexpression of PRODH restores the ferroptosis in tamoxifen-resistant cells. Moreover, Ferrostatin-1 (Fer-1), the ferroptosis inhibitor, reversed the effect of PRODH on tamoxifen resistance.
Conclusions
These findings suggest that PRODH regulates tamoxifen resistance by regulating ferroptosis in tamoxifen-resistant cells.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Department of Biochemistry, Medicine School, Yichun University, Yichun 336000, China.
ORCID-Profile: Ping Zhang, Kuaiying Wu, Xiaofeng Luo, Mengqi Liu, Jiajun Cui
Förderung
- National Natural Science Foundation of China
- Education Department of Jiangxi Province
- Science and Technology project of Education Department of Jiangxi Province
Zitieren
APA
Zhang, P., Qian, N., Lai, H., Chen, S., Wu, K., Luo, X., Lei, B., Liu, M., & Cui, J. (2024). PRODH Regulates Tamoxifen Resistance through Ferroptosis in Breast Cancer Cells. Genes. https://doi.org/10.3390/genes15101316
Vancouver
Zhang P, Qian N, Lai H, Chen S, Wu K, Luo X, et al. PRODH Regulates Tamoxifen Resistance through Ferroptosis in Breast Cancer Cells. Genes. 2024. doi:10.3390/genes15101316
BibTeX
@article{Zhang2024,
author = {Zhang, Ping and Qian, Na and Lai, Haigen and Chen, Shu and Wu, Kuaiying and Luo, Xiaofeng and Lei, Bo and Liu, Mengqi and Cui, Jiajun},
title = {PRODH Regulates Tamoxifen Resistance through Ferroptosis in Breast Cancer Cells},
journal = {Genes},
year = {2024},
doi = {10.3390/genes15101316}
}
EUVIMED